Spark Therapeutics, Inc. (ONCE) stock prices updated...
 

Spark Therapeutics, Inc. stock price

Spark Therapeutics, Inc. latest news:


  • 11/10/2017 15:26:29

    BRIEF-Spark Therapeutics says 3-year follow-up phase 3 data provide additional information on Luxturna

    Spark Therapeutics Inc(ONCE): * Three-Year follow-up phase 3 data provide additional information on efficacy, durability and safety of investigational Luxturna in patients with biallelic RPE65-mediated inherited retinal disease Source text for Eikon: Further company coverage:

  • 10/13/2017 05:41:21

    Spark Therapeutics shares jump 7.5% after FDA committee backs blindness treatment

    Shares of Spark Therapeutics Inc. surged 7.5% premarket Friday, after a U.S. Food and Drugs Administration advisory committee recommended approval of the company's gene therapy treatment for a rare eye disease that causes blindness. The committee voted unanimously to approve Luxturna in the treatment of patients with biallelic RPE65-mediated inherited retinal disease. There is currently no treatment for the disease, which causes childhood blindness. Luxturna has received orphan drug, breakthrough therapy and rare pediatric disease designations from the agency. The treatment showed positive results in a Phase 3 trial, data from which were published in The Lancet. The committee's ruling is non-binding, but is taken into consideration by the FDA when reviewing drug applications. Shares have gained 73% in 2017, while the S&P 500 has gained 14%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • More trends:

    Spartan Motors, Inc.SPAR | SpartanNash CompanySPTN | Spectrum Pharmaceuticals, Inc.SPPI | Speed Commerce, Inc.SPDC | Sphere 3D Corp.ANY | Spherix IncorporatedSPEX | Spirit Airlines, Inc.SAVE | Splunk Inc.SPLK | Spok Holdings, Inc.SPOK | Sportsman's Warehouse Holdings, Inc.SPWH |